Buprenorphine Transition After Injury: Attorney Guide to MAT in PI

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 8 min read

Transitioning PI patients from full agonist opioids to buprenorphine is an established clinical strategy for safe long-term recovery. This guide helps attorneys understand the clinical timeline, address MAT stigma, and document buprenorphine transitions for settlement purposes.

Buprenorphine transition therapy is the medically supervised process of moving a personal injury patient from full agonist opioids (oxycodone, hydrocodone, morphine) to buprenorphine — a partial mu-opioid agonist — to achieve safer long-term pain management with lower overdose risk and reduced tolerance development. For PI attorneys, understanding this transition is essential because it represents both a clinical milestone in the patient's treatment and a potential defense attack vector if the stigma surrounding buprenorphine is not proactively addressed.

• Buprenorphine transition in PI cases involves switching from Schedule II opioids to buprenorphine formulations (Belbuca for pain, Subutex/Suboxone if opioid dependence has developed) under specialist supervision, typically over a 3-14 day induction period
• The FDA recognizes buprenorphine as both a chronic pain treatment (Belbuca, Butrans) and a medication-assisted treatment for opioid use disorder (Suboxone, Sublocade), and both contexts are clinically legitimate outcomes of injury-related opioid therapy (FDA.gov prescribing information)
• LienScripts covers all buprenorphine formulations on pharmacy lien and generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the full opioid-to-buprenorphine transition timeline
• According to James Wong, PharmD, founder of LienScripts, "Defense counsel will try to reframe a buprenorphine transition as evidence of addiction rather than evidence of injury severity — attorneys need to get ahead of that narrative with clinical documentation"
• An estimated 8-12% of patients prescribed opioids for more than 90 days develop opioid use disorder (Vowles et al., Pain, 2015), making buprenorphine transition a foreseeable consequence of serious injury treatment

The Clinical Timeline: Injury to Buprenorphine

Understanding the typical progression helps attorneys frame the narrative:

Phase 1: Acute Opioid Therapy (Weeks 1-8)

The patient receives opioids for acute injury pain — typically hydrocodone or oxycodone prescribed by the ER physician or treating orthopedist. This is standard, uncontroversial care.

Phase 2: Chronic Opioid Therapy (Months 2-6+)

As injuries persist — particularly spinal, nerve, or multi-site injuries — opioid therapy extends beyond the acute phase. The patient may be referred to pain management. Tolerance develops, doses increase, and side effects accumulate.

Phase 3: Clinical Decision Point

The pain specialist recognizes that continued full agonist therapy carries escalating risk. The decision to transition to buprenorphine may be driven by:

• Safety concerns — the patient's dose has reached levels where respiratory depression risk is significant
• Tolerance management — pain control is declining despite dose increases
• Functional goals — buprenorphine's partial agonist profile produces less cognitive impairment, supporting return to work or daily activities
• Opioid use disorder — physiological dependence has progressed to the point where the patient meets DSM-5 criteria for OUD

Phase 4: Buprenorphine Induction (Days 1-14)

The transition requires the patient to enter mild opioid withdrawal before buprenorphine can be initiated (to avoid precipitated withdrawal). This induction period is uncomfortable and requires close medical management. It typically occurs over 3-14 days depending on the protocol used.

[!KEY] The buprenorphine induction period is itself evidence of injury impact. The patient must endure managed withdrawal — nausea, pain, anxiety, insomnia — as a direct consequence of the opioid therapy that was necessitated by their injuries. This suffering is compensable and should be documented in the demand package.

Phase 5: Buprenorphine Maintenance

Once stabilized on buprenorphine, the patient continues maintenance therapy. For pain-only cases, this may be Belbuca or Butrans. For patients with OUD, this may be Suboxone or Sublocade (extended-release injection). Maintenance may continue for months to years.

Addressing the MAT Stigma in PI Cases

The most significant challenge attorneys face when buprenorphine appears in a PI file is stigma. Defense counsel, adjusters, and even jurors may associate buprenorphine exclusively with "drug addiction" and discount the patient's injuries accordingly.

The clinical reality is different:

Opioid dependence is a physiological inevitability, not a moral failing. Any patient taking opioids daily for more than 2-3 weeks will develop physical dependence. This is basic pharmacology — the body adapts to the presence of the drug. Physical dependence is distinct from addiction (opioid use disorder), though the two can coexist.

OUD after injury is a foreseeable harm. If the patient developed OUD as a result of opioids prescribed for their injuries, the defendant bears responsibility. The buprenorphine treatment is additional medical expense and evidence of additional harm caused by the accident.

Buprenorphine is evidence-based medicine, not weakness. The Substance Abuse and Mental Health Services Administration (SAMHSA), the American Society of Addiction Medicine, and the FDA all recognize medication-assisted treatment as the gold standard for OUD.

[!TIP] In the demand package, proactively address the buprenorphine narrative. Include a section titled "Opioid Transition Therapy" that explains the clinical rationale, cites the treating physician's documentation, and frames the transition as evidence of injury severity. Do not wait for the defense to raise it as an attack.

Pharmacy Lien Coverage for Buprenorphine Transition

Insurance coverage for buprenorphine is notoriously complex:

• Pain formulations (Belbuca, Butrans) face prior authorization barriers and formulary restrictions
• MAT formulations (Suboxone, Sublocade) may require documentation of OUD diagnosis, which the patient may resist due to stigma
• Induction medications (comfort medications for withdrawal management) may not be covered under the patient's plan

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The transition from opioids to buprenorphine often involves multiple medications — the buprenorphine itself, comfort medications for induction, and sometimes bridging pain medications. Insurance rarely covers this seamlessly. The pharmacy lien ensures the patient has uninterrupted access to every medication in the transition protocol."

LienScripts covers the complete buprenorphine transition on pharmacy lien, including induction comfort medications, the buprenorphine formulation selected by the treating physician, and any adjunctive medications prescribed during stabilization.

Documentation for the Demand Package

Attorneys should compile:

1. Pain management records documenting the clinical rationale for the opioid-to-buprenorphine transition
2. Pharmacy lien records showing the full medication timeline: initial opioids, dose escalation, transition to buprenorphine, and ongoing maintenance
3. The MERIT report from LienScripts, which presents the medication chronology with clinical context
4. Treating physician statement explaining that the buprenorphine need was caused by the injury and subsequent opioid therapy

The medication timeline alone — from the first opioid prescription days after the accident through the buprenorphine transition months later — tells a compelling story of escalating treatment needs driven by injury severity.

Legal Theories for Buprenorphine-Related Damages

The buprenorphine transition supports several damage categories:

• Additional medical expenses — the cost of MAT/buprenorphine therapy, physician monitoring, and associated medications
• Pain and suffering — the induction withdrawal period and the ongoing burden of daily medication management
• Future medical expenses — buprenorphine maintenance may be required for years, and the cost of ongoing treatment is a foreseeable future expense
• Loss of enjoyment of life — daily medication requirements, pharmacy visits, and the social stigma of buprenorphine therapy all diminish quality of life

[!KEY] If the patient developed OUD requiring buprenorphine treatment as a direct result of opioids prescribed for their injuries, the buprenorphine therapy and all associated costs are additional special damages attributable to the defendant. This is not a preexisting condition — it is a consequence of the injury.

FAQs

Related Resources

• Buprenorphine for Chronic Pain After an Accident
• Opioid Rotation Therapy: Pharmacy Lien Strategy
• Opioid Prescribing Guidelines in Personal Injury Cases
• What Is a Pharmacy Lien?